Julia Rotow MD (@JuliaRotow) ranks #21 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 15 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $109,349 in 2025 general payments.
At a Glance
- 3 colleague posts sharing slides from Julia Rotow MD's presentations
- Lung Cancer: US #21, Global #47 · 15 physicians engaged
- Presented at WCLC 2026, ASCO 2026 in 2026
- CMS Open Payments lists $109,349 in 2025 general payments.
This Month
What Julia Rotow MD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #21 | #47 | 15 | 18 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Julia Rotow MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · Plenary (PL03.08)DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results
- ASCO 2026 · Rapid oral (8519)Silevertinib (BDTX-1535): Safety and Efficacy in Treatment-Naive NSCLC with Non-Classical EGFR MutationsSource: @StephenVLiu on X ↗
What Colleagues Are Saying About Julia Rotow MD
2026 posts by fellow physicians that mention @JuliaRotow, quoted word for word.
🆙#WCLC26 #LCSM Plenary Session 🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results 🎙️ @JuliaRotow 🔢PL03.08 🎯T-DXd Showed Statistically Significant and Clinically Meaningful PFS Improvement vs SOC (Chemo+Pembrolizumab) as First-Line Therapy ☑️NCT05048797 🔗 https://t.co/gAahGHJGeA @OncoAlert @Larvol @IASLC
#ASCO26 Dr. @JuliaRotow presents phase II study of 1L silevertinib (BDTX-1535) in NSCLC with non-classical EGFR NSCLC (n=43, 58% PACC, 37% compound). AEs include known EGFR related toxicity, 14% d/c from AE. RR 60% with PFS 15.2m, mDOR NR, 80% CNS response rate. https://t.co/rFJ3n7apxT
Dr. @JuliaRotow makes her case for FLAURA2 osimertinib+chemotherapy in EGFRm NSCLC at #WinterLung26. Benefit extends beyond classical "high risk" subgroups. https://t.co/meVl7Flh3y
Debating whether to use NEOADAURA vs LAURA @JSabari @JuliaRotow which one should we choose? @Joshua_Reuss @StephenVLiu @chulkimMD #DCLung26 https://t.co/jIVkSkxLvC
Following on the primary trial data presented by @JuliaRotow at #WCLC26, #Destiny_Lung04 #PROMs were reported by Dr. #SilviaNovello showing improved patients reported outcomes in patients treated with #T_DXd over #chemo_IO. #LCSM 🫁 #ESMO26 @myesmo #ESMOAmbassadors https://t.co/38VGaQlL5b
Dr @JuliaRotow with terrific presentation of DESTINY-Lung04 #WCLC26. ORR 70% vs 44.5%, improved PFS. ‼️No significant OS benefit ; notably, 48% of chemo arm did receive subsequent HER2 directed treatment 🚨ILD any grade 20.8% (78.7% G 1/2) ⭐️Zongertinib my choice for 1L treatment in HER2 TKD alterations
Julia Rotow MD’s Presentations
Slides from Julia Rotow MD’s 2026 presentations, as shared by physicians in the audience.
Dr. Julia Rotow @JuliaRotow presents the DESTINY-Lung-04 data of trastuzumab deruxtecan vs pembro+chemo in 1L HER2 NSCLC at @IASLC #WCLC26. T-DXd improved PFS and ORR, yet OS benefit is limited with this regimen, likely confounded by access to 2L HER2-directed therapies. AEs https://t.co/vVPHm95iek
Dr. @JuliaRotow presents Ph3 DESTINY-Lung04 T-DXd vs Pembro-chemo #WCLC26. ✅️ PFS 14.3 vs 8.3mo (HR 0.63) ✅️ ORR 7O vs 45% ☑️ No OS diff observed 1st ph3 study for HER2-targeted Rx in adv HER2m NSCLC. Efficacy by mutation type & CNS efficacy will help in agent selection. https://t.co/wRbyeY4eZd
Dr. @JuliaRotow presents DESTINYLung04, 1L T-DXd in HER2 mt NSCLC. Study met its primary endpoint of mPFS, 14.3 vs 8.3 mo, HR 0.63; P<0.0001. No OS benefit but durability and response favored T-DXd. ILD and ♥️ AEs require awareness and close monitoring @IASLC #WCLC26 #LCSM https://t.co/615R1IXBwO
Industry Payments
CMS Open Payments · 2025 general payments
$109,349 across 76 payments